For the advanced melanoma, current therapeutics such as BRAF inhibitors, cytotoxic T lymphocyte-associated antigen 4 antibody and interleukin-2 biological therapy show different toxicities and side-effects3, 4, 5. This evidence concerns the gene BRAF and melanoma.